Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
HIV-1 Inhibitor
CGP-75355 is a potent inhibitor of HIV-1 protease, exhibiting an IC50 of 26 nM. This bis(L-tert-leucine) derivative effectively disrupts viral replication, making it a valuable tool for studying HIV-1 protease function and for the development of antiviral therapies. Its specificity and efficacy position CGP-75355 as a critical reagent in HIV research applications. -
HIV-1 Replication Inhibitor
DQBS is an inhibitor targeting the HIV-1 Nef protein, which plays a critical role in HIV replication. By binding to Nef, DQBS effectively inhibits the Nef-dependent processes essential for viral replication. This compound is valuable for research aimed at understanding HIV pathogenesis and developing therapeutic strategies to combat HIV infection. -
HIV Inhibitor
GSK-364735 potassium is a potent HIV integrase inhibitor, targeting the integrase enzyme of human immunodeficiency virus type 1 (HIV-1) with an IC50 of 7.8 nM. This compound plays a crucial role in antiretroviral research by disrupting viral replication and integration processes. Its application extends to the development of therapeutic strategies against HIV, making it a valuable tool for researchers in the field of virology and infectious disease. -
HIV Inhibitor
CGP 57813 is a peptidomimetic inhibitor of HIV protease, designed to interfere with viral replication. This compound exhibits potential in therapeutic applications targeting HIV infection. Its ability to be encapsulated in nanoparticles made from poly(D,L-lactic acid) and pH-sensitive methacrylic acid copolymers enhances its delivery and stability within biological systems. -
HIV-1 Inhibitor
JTK-101 is a selective inhibitor of HIV-1, primarily targeting Tat cofactors such as CDK9 and cyclin T1. By inhibiting these cofactors, JTK-101 effectively reduces HIV-1 mRNA synthesis and suppresses the transcriptional activity of the virus. This compound is valuable for research applications focused on anti-HIV therapeutic strategies and understanding HIV transcription regulation. -
HIV-1 Inhibitor
L-708906 is a potent inhibitor of human immunodeficiency virus type 1 (HIV-1) with an IC50 value of 12 μM. This compound effectively inhibits HIV strains that are resistant to both nonnucleoside and nucleoside reverse transcriptase inhibitors. L-708906 is useful in research applications focused on the development of new therapeutic strategies for HIV treatment and resistance management. -
HIV Inhibitor
Salaspermic acid is a triterpene acid derived from Salacia macrosperma Wight, functioning as an inhibitor of HIV reverse transcriptase. This compound demonstrates significant antiviral activity by effectively reducing HIV replication in H9 lymphocyte cells. Salaspermic acid serves as a valuable tool for research focused on HIV pathogenesis and therapeutic development. -
HIV-1 Reverse Transcriptase Inhibitor
Mesoxalate, a dicarboxylic and ketonic acid, serves as an inhibitor of HIV-1 reverse transcriptase (RT). It exerts biological activity with an IC50 value of 2.2 μM, making it a valuable tool for studying the inhibition of HIV replication. Mesoxalate is applicable in research focusing on antiviral therapies targeting retroviral enzymes. -
HIV-1 Inhibitor
RDEA-427 is a pyrrolopyrimidine derivative that acts as a non-nucleoside reverse transcriptase inhibitor (NNRTI) targeting HIV-1. This compound demonstrates efficacy against both wild-type and NNRTI-resistant mutant strains of HIV-1. RDEA-427 is suitable for research applications focused on HIV infection and the mechanisms of viral resistance. -
HIV-1 Reverse Transcriptase Inhibitor
L-702007 is a potent inhibitor of HIV-1 reverse transcriptase, a critical enzyme in the life cycle of the HIV virus. By obstructing viral replication, it exhibits significant antiviral activity, making it a valuable tool in HIV research. This compound is instrumental in studying the mechanisms of HIV infection and testing potential antiviral therapies. -
HIV Inhibitor
Adenallene is a nucleoside analogue that functions as an anti-HIV agent. It effectively inhibits the replication of both HIV-1 and HIV-2, demonstrating the ability to reduce cytopathic effects associated with these viruses. This compound is valuable for research focused on antiviral drug development and HIV pathogenesis studies. -
HIV-1 Inhibitor
GSK878 is a highly potent HIV-1 inhibitor that exerts its antiviral effects through the selective targeting of viral replication mechanisms. With an EC50 value of 39 pM, it demonstrates strong efficacy in suppressing HIV-1 activity. This compound is utilized in research for its potential applications in the development of long-acting therapeutic strategies for HIV treatment. -
HIV Inhibitor
HIV-IN-8 is an effective HIV inhibitor that targets the replication process of the virus. With an EC50 value of 13 μg/mL, this compound demonstrates a significant capacity to inhibit HIV replication in vitro. It is suitable for research applications focused on understanding HIV biology and evaluating antiviral strategies. -
HIV-1 IN Inhibitor
Hyrtiosal is a potent inhibitor of the N-terminal domain (NTD) of HIV-1 integrase (HIV-1 IN), exhibiting an IC50 value of 9.60-0.86 μM. By specifically binding to the Ser17, Trp19, and Lys34 residues on the NTD, Hyrtiosal effectively disrupts the interaction between HIV-1 viral DNA and integrase, thus hindering the formation of the pre-integrated complex essential for viral replication. This compound is valuable for research focused on discovering and developing novel anti-HIV therapeutics. -
HIV-1 Reverse Transcriptase Inhibitor
NNRT-IN-10 is a potent, selective non-nucleoside inhibitor of HIV-1 reverse transcriptase, demonstrating EC50 values ranging from 1.16 to 18.3 nM against HIV and its mutant strains. This compound exhibits favorable pharmacokinetic properties and safety profiles, making it suitable for research applications in studying HIV-1 and AIDS. NNRT-IN-10 represents a crucial tool for advancing antiviral research targeting HIV-1 replication. -
HIV Protease Inhibitor
BMS 186318 is a potent HIV protease inhibitor that plays a critical role in blocking viral replication by interfering with the proteolytic processing of viral polyproteins. This compound demonstrates enhanced anti-HIV efficacy when used in conjunction with reverse transcriptase inhibitors and additional protease inhibitors. BMS 186318 is ideal for applications in antiviral research, contributing to the development of effective therapeutic strategies against HIV. -
HIV-1 integrase Inhibitor
MK-0536 is a potent inhibitor of HIV-1 integrase, demonstrating significant efficacy in suppressing the replication of wild-type viruses. This compound retains antiviral activity against several drug-resistant mutants, including Y143R and N155H, while exhibiting no cytotoxic effects on uninfected cells. MK-0536 operates by selectively blocking the strand transfer reaction of integrase through magnesium ion chelation at the active site, as well as interactions with viral DNA and integrase residues. This reagent is valuable for investigating the mechanisms underlying HIV infection and resistance. -
HIV-1 Reverse Transcriptase Inhibitor
TSAO-T is a potent inhibitor of HIV-1 reverse transcriptase, a key enzyme in the retroviral replication cycle. By disrupting this enzyme's activity, TSAO-T effectively impedes viral replication, making it a valuable tool in HIV research. Its use can facilitate the study of HIV infection mechanisms and the development of novel therapeutic strategies. -
HIV-1 nucleotide reverse transcriptase Inhibitor
GS-9148 is a ribose-modified inhibitor of HIV-1 nucleotide reverse transcriptase, exhibiting an EC50 value of 10.6 µM. This compound demonstrates significant antiretroviral activity against HIV-1 strains with mutations at K65R, L74V, and M184V. GS-9148 is a valuable tool for research focused on HIV resistance mechanisms and the development of novel therapeutic strategies. -
HIV Attachment Inhibitor
BMS-663749 is an HIV attachment inhibitor that functions as a phosphonooxymethyl prodrug of BMS-488043. This compound effectively interferes with the binding of the HIV virus to host cells, thereby preventing viral entry and infection. BMS-663749 is primarily utilized in research focused on HIV biochemistry and therapeutic development strategies targeting viral attachment processes. -
HIV-1 Inhibitor
A-75925 is a selective inhibitor of the HIV-1 protease, a key enzyme in the viral replication process. By interfering with the protease activity, A-75925 effectively inhibits HIV-1 replication, making it a valuable tool in HIV research. This compound can be employed to investigate antiviral strategies and the mechanisms underlying HIV resistance. -
HIV-1 Inhibitor
N.41 is an HIV-1 inhibitor that functions by disrupting the interaction between the viral Vif protein and the host antiviral factor APOBEC3G (A3G). By protecting A3G from Vif-mediated degradation, N.41 increases cellular levels of A3G and enhances its incorporation into viral particles, resulting in reduced HIV-1 infectivity. This compound demonstrates significant antiviral activity against HIV-1 replication in peripheral blood mononuclear cells (PBMCs), with an IC50 value of 8.4 μM, highlighting its potential for research applications in HIV-1 studies and antiviral drug development. -
HIV-1 Inhibitor
NBD-10007 is a CD4 agonist that specifically targets HIV-1. It demonstrates significant anti-HIV-1 viral activity, making it a valuable reagent for studying HIV pathogenesis and testing potential therapeutic interventions. Its unique mechanism of action may provide insights into CD4 receptor modulation and immune responses in HIV infection research. -
HIV-1 Inhibitor
BMS 488043 is an orally active inhibitor that targets the attachment process of human immunodeficiency virus type 1 (HIV-1) to CD4+ lymphocytes. It exhibits strong antiviral activity by preventing viral entry, making it a valuable tool for research into HIV-1 transmission and infection dynamics. This compound is suitable for studies focusing on the development of therapeutic strategies against HIV-1. -
HIV-1 Inhibitor
Methyl salvionolate A is a potent inhibitor of HIV-1 that targets multiple viral enzymes. It demonstrates significant activity by inhibiting the production of P24 antigen in HIV-1 infected MT-4 cells with an EC50 value of 1.62 μg/ml. Additionally, Methyl salvionolate A effectively inhibits HIV-1 reverse transcriptase, protease, and integrase, with corresponding IC50 values of 50.58, 10.73, and 7.58 μg/ml, respectively. This compound is valuable for research into HIV-1 antiviral strategies and the development of therapeutic agents. -
HIV Nef Inhibitor
DLC27-14 is an HIV Nef inhibitor with an IC50 value of 15.92 μM, effectively disrupting the function of the Nef protein in HIV-1. This compound is valuable for research focused on HIV pathogenesis and exploring therapeutic strategies targeting viral replication. Its mechanism of action provides insights into the role of Nef in HIV dynamics and potential avenues for antiviral drug development. -
HIV-1 Inhibitor
TNK-651 is a non-nucleoside inhibitor of HIV-1 reverse transcriptase, effectively blocking viral replication. It demonstrates inhibitory activity against both the HIV-1 SF33 strain and the NNRTI-resistant HIV-1 A17 strain. TNK-651 is valuable for research applications focusing on HIV-1 infection and resistance mechanisms. -
HIV Inhibitor
12-Methoxydodecanoic acid is an HIV inhibitor that exhibits anti-viral activity with an IC50 of 6.8 μM. This compound, a heteroatom-containing analog of myristic acid, has also been shown to inhibit the moloney murine leukemia virus (MoMLV). Its unique properties make it suitable for research into viral inhibition mechanisms and therapeutic development in HIV-related studies. -
HIV Inhibitor
GSK163929 is an orally bioavailable CCR5 antagonist, primarily targeting HIV infection. This compound demonstrates anti-HIV activity by inhibiting the CCR5 co-receptor, crucial for viral entry into host cells. GSK163929 has been evaluated for safety, showing no adverse effects in rat and dog models at specified dosages. Its properties make it a valuable tool for research in HIV therapies and co-receptor interaction studies. -
HIV-1 RT Inhibitor
L-697639 is a potent inhibitor of HIV-1 reverse transcriptase (HIV-1 RT), exhibiting an IC50 range of 20-400 nM in a template-primer-dependent manner. This compound demonstrates significant antiviral activity, effectively inhibiting up to 95% of HIV-1 infection in human T lymphocyte cultures at concentrations between 12-200 nM. L-697639 is a valuable tool for research applications focused on HIV-1 therapy and the mechanisms of viral replication. -
HIV gp120 Inhibitor
Chloropeptin I is an inhibitor of the HIV glycoprotein 120 (gp120), blocking its binding to the CD4 receptor with an IC50 of 2.0 μM. This compound exhibits selective anti-HIV activity, making it a valuable tool for research into HIV transmission and infection mechanisms. It serves as an important reagent for studying potential therapeutic strategies targeting HIV entry into host cells. -
HIV-1 Inhibitor
HIV-1-IN-86 is an HIV-1 inhibitor that targets viral replication. With an EC50 value of 0.77 μM, this compound exhibits significant antiviral activity against HIV-1. It is a valuable tool for research applications aimed at understanding HIV-1 biology and developing antiviral therapies. -
HIV-1 Protease Inhibitor
SDZ283-910 is a potent inhibitor of HIV-1 protease, targeting a crucial enzyme in the viral replication cycle. By disrupting the proteolytic processing of viral proteins, SDZ283-910 exhibits significant antiviral activity against HIV-1. This compound is valuable for research applications focused on understanding HIV biology and developing antiviral therapies. -
HIV-1 Inhibitor
HIV-1-IN-82 is a small-molecule entry inhibitor targeting HIV-1 with an IC50 value of 0.39 μM. This compound demonstrates potent antiviral activity, making it a valuable tool for research focused on anti-HIV-1 infection. It is suitable for studies investigating mechanisms of viral entry and the development of novel therapeutic strategies against HIV-1. -
HIV Inhibitor
GSK-364735 sodium is a potent inhibitor of the integrase enzyme of human immunodeficiency virus type 1 (HIV-1), demonstrating an IC50 value of 7.8 nM. As an antiretroviral agent, it serves as a valuable tool for studying HIV-1 replication and therapeutics. This compound is essential for researchers investigating integrase inhibition and its implications in HIV treatment strategies. -
HIV Integrase Inhibitor
PF-4776548 is a potent inhibitor of HIV integrase, a crucial enzyme in the integration of viral DNA into the host cell genome. By blocking this integration process, PF-4776548 demonstrates significant potential in the study of HIV replication and the mechanisms of AIDS pathogenesis. This compound is valuable for research applications aimed at developing antiviral strategies and understanding HIV-related diseases. -
HIV Inhibitor
Scirpusin A is a naturally derived compound from the legume Caragana rosea Turcz, recognized for its anti-HIV properties. It exhibits substantial inhibitory activity against HIV-1, with an effective concentration (EC50) of 7 μg/mL. Scirpusin A serves as a valuable tool in the research and development of novel anti-HIV therapeutics, contributing to the understanding of potential treatment options. -
HIV-1 Protease Inhibitor
LY-326188 is a potent inhibitor of HIV-1 protease, exhibiting an IC50 of 0.42 nM. It effectively protects HIV-1 infected cells from viral replication. This compound is valuable for research aimed at understanding HIV biology and developing antiviral therapeutics. -
HIV Inhibitor
KRH-3955 is a potent CXCR4 antagonist that demonstrates significant anti-HIV-1 activity, particularly against X4 strains. It effectively inhibits the replication of various X4 HIV-1 clinical isolates and is active against recombinant strains with resistance mutations in reverse transcriptase, protease, and tyrosinase. KRH-3955 disrupts the binding of SDF-1alpha to CXCR4, thereby interfering with calcium signaling through this receptor, along with inhibiting antibody binding to CXCR4. With an oral bioavailability of 25.6% in rats, KRH-3955 has shown efficacy in vivo, making it a valuable tool for HIV research. -
HIV-1 Protease Inhibitor
HIV-1 protease-IN-15 is a selective inhibitor of HIV-1 protease, exhibiting a pIC50 value of 9.347. This compound effectively inhibits the maturation of HIV proteins, thereby blocking viral replication. It serves as a valuable tool for research on HIV-1 infection and potential therapeutic interventions. -
HIV-1 RT Inhibitor
7-Deaza-2',3'-dideoxyguanosine is an inhibitor of HIV-1 reverse transcriptase, functioning as a 2′,3′-dideoxynucleoside 5′-triphosphate. It demonstrates potent antiviral activity with an inhibition constant (Ki) of 25 nM, making it a valuable tool for research into HIV replication and reverse transcription processes. This compound is particularly useful for studies aimed at understanding the mechanisms of HIV resistance and the development of antiviral therapies. -
HIV Protease Inhibitor
MK-8718 is a potent and orally bioavailable HIV protease inhibitor that features a morpholine aspartate binding group. This compound effectively inhibits the activity of HIV protease, making it a valuable tool for studying HIV infection and antiretroviral therapy mechanisms. Its application in research may enhance the understanding of HIV replication and contribute to the development of novel therapeutic strategies. -
HIV Protease Inhibitor
PAC-Phe-Val is a potent inhibitor of HIV-1 protease, exhibiting an IC50 value of 33.10 nM. It establishes stable interactions with key active site residues, which enhances its inhibitory efficacy. This compound is suitable for research applications focused on HIV/AIDS and provides significant potential for therapeutic development in this area. -
HIV-1 Inhibitor
Hinokinin is a compound derived from the stems of Hypoestes aristata, primarily targeting the HIV-1 protease enzyme. It demonstrates moderate inhibitory activity against HIV-1, making it a potential candidate for antiviral research. This compound can be utilized in studies aimed at understanding the mechanisms of HIV-1 replication and developing therapeutic strategies against HIV infection. -
HIV protease inhibitor
Brecanavir is a potent inhibitor of HIV protease, a crucial enzyme in the HIV life cycle. By inhibiting this enzyme, Brecanavir effectively reduces viral replication, making it a valuable compound in HIV research and therapeutic development. Its potential applications include studying drug resistance mechanisms and exploring combination therapies for enhanced antiviral efficacy. -
Anti-HIV Nucleoside Reverse Transcriptase Inhibitor
CL-197 is a purine-based nucleoside reverse transcriptase inhibitor (NRTI) that exhibits anti-HIV activity through its selective inhibition of viral reverse transcriptase. This compound has potential applications in studying viral, oncological, and cerebrovascular diseases. Additionally, CL-197 serves as a click chemistry reagent, featuring an alkyne group that allows for copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules, facilitating advanced chemical research. -
HIV-1 Protease Inhibitor
TMC310911 is a potent and orally bioavailable inhibitor of the HIV-1 protease. It exhibits significant antiviral activity, with EC50 values ranging from 2.2 nM to 14.2 nM against wild-type HIV-1. Additionally, TMC310911 demonstrates effective activity against a broad range of recombinant HIV-1 isolates, making it a valuable tool for research on HIV-1 infection and resistance development. -
HIV Protease Inhibitor
Isoescin IA is a triterpenoid saponin derived from the seeds of Aesculus chinensis, functioning as an HIV protease inhibitor. This compound exhibits significant anti-HIV-1 protease activity, making it a valuable tool for research aimed at understanding HIV replication and potential therapeutic strategies. Its selective inhibition of the protease can aid in the investigation of antiviral mechanisms and drug development in the field of HIV research. -
HIV Protease Inhibitor
Ganodermanondiol is an HIV protease inhibitor derived from Ganoderma lucidum. It demonstrates significant anti-HIV-1 protease activity, with an IC50 of 90 μM, making it a valuable compound for antiviral research. Additionally, Ganodermanondiol exhibits strong cytoprotective effects against tert-butyl hydroperoxide-induced hepatotoxicity and showcases anticomplement activity against the classical pathway of the complement system, with an IC50 of 41.7 μM. This compound is relevant for studies focused on hepatoprotection and immune modulation. -
HIV-1 Protease Inhibitor
SKF107457 is a potent inhibitor of HIV-1 protease, a key enzyme critically involved in the viral replication process. This compound exhibits significant antiviral activity against HIV-1, making it valuable for studying the mechanisms of HIV infection and resistance. Additionally, SKF107457 can be utilized in research focused on developing new therapeutic strategies for AIDS.
